Serum vascular endothelial growth factor associated with the progression of granulosa cell tumor: A report of two cases

Author:

Takasaki Kazuki1,Ichinose Takayuki1,Miyagawa Yuko1,Fukui Shiho1,Hashimoto Kei1,Takahashi Yuko1,Nishida Haruka1,Hirano Mana1,Hiraike Haruko1,Saito Koji1,Sasajima Yuko1,Nagasaka Kazunori1

Affiliation:

1. Teikyo University School of Medicine

Abstract

Abstract Background: Granulosa cell tumors (GCTs) account for approximately 2% of ovarian malignancies and are considered a rare type of ovarian cancer. GCTs are characterized by irregular genital bleeding after menopause due to female hormone production as well as late recurrence around 5–10 years after initial treatment. In this study, we investigated two cases of GCTs to find a biomarker that can be used to evaluate the treatment and predict recurrence. Case presentation: Case 1 was a 56-year-old woman who presented to our hospital with abdominal pain and distention. An abdominal tumor was found, and GCTs were diagnosed. Serum vascular endothelial growth factor (VEGF) levels decreased after surgery. Case 2 involved a 51-year-old woman with refractory GCTs. Carboplatin–paclitaxel combination therapy and bevacizumab were administered after the tumor resection. After chemotherapy, a decline in VEGF levels was observed, but serum VEGF levels increased again with disease progression. Conclusion: VEGF expression may be of clinical importance in GCTs as a clinical biomarker for disease progression, which may be used to determine the efficacy of bevacizumab against GCTs.

Publisher

Research Square Platform LLC

Reference17 articles.

1. Granulosa cell tumor of the ovary;Schumer ST;J Clin Oncol,2003

2. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report;Barrena Medel NI;Anticancer Res,2010

3. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors;Tao X;Gynecol Oncol,2009

4. Molecular pathogenesis in granulosa cell tumor is not only due to somatic FOXL2 mutation;Wang WC;J Ovarian Res,2014

5. Clinicopathological characteristics and prognosis of adult ovarian granulosa cell tumor: a single-institution experience in China;Wang D;Onco Targets Ther,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3